Phase IIb Glioblastoma trial has successfully completed all enrollment and treatment

Mar 12, 2026News

NovOx Therapeutics reports that its Phase IIb Glioblastoma trial has successfully completed all enrollment and treatment. The Company’s commitment to patients does not stop there.

Learn the Full Story here!

← Previous Post Next Post →

Latest News

A Field Guide to Tourist Capital
Your Brilliant Solution is Just the Start in Fundraising.
Pyx Health Named to the Inc. 5000 List for the 5th Year in row
The K-Shaped Meat Grinder – What a Record Venture Market Means for Regions That Will Never See It
Linshom Medical Awarded Commercialization Innovation Grant
Somewhere Right Now a Surgeon is Learning a Procedure for the Very First Time on a Real Person. ReSuture Changes This!
Are Ecosystem Leaders Wasting Money on Accelerators?
Regional Ecosystems Operate Inside an Accountability Vacuum
NuvOx Therapeutics Receives FDA Fast Track Designation to NanO₂™ for the Treatment of Acute Ischemic Stroke
$200MM and Counting: What’s Next for the Movement to Invest in Women Entrepreneurs
Moving Beyond Performative Entrepreneurship
iQure Pharma has received a research grant from the The Michael J. Fox Foundation for Parkinson’s Research
Delta Development Team Milestone Achievement
iQure Pharma Inc. Chief Scientific Officer recently published
NuvOx Announces Positive Completion of 2nd Cohort in EXTEND-1b Trial
Time to Update the Model – The Aging Angel Investment Thesis
CircleIn – Q1 2026 Investors and Advisors Update
Shrinking failure rates = lives changed!
Patent Award Marks Key Milestone for Delta Development Team’s Autonomous Portable Refrigeration Unit
What if blood logistics moved at the speed of maneuver – powered by batteries?
Phase IIb Glioblastoma trial has successfully completed all enrollment and treatment
Mitigating the Decline in Angel Board Representation – Angel view Point
Mitigating the Decline in Angel Board Representation
Top 100 Angel Investment Group Investment Thesis
Delta Development Team Equips Kenosha WI EMS Carry Blood to the Frontline
NuvOx Announces Positive Results 1st Cohort Phase Ib Trial
Tech Parks Arizona Economic Impact
Delta Development Team Exceeds New Prehospital Blood Transfusion Standards
Clinical Trial Confirms GammaTile Superior Tumor Control
2025 Brutal Biotech Investment Climate
CircleIn 2025-Q4 Investor Update
NuvOx and FYR Bio Announce NCI Funding
Delta Development Team – Introducing BloodCOMM Premium
Special Operations Forces Blood Cooler from Delta Development
UACI startup alumni Reglagene making impressive strides in brain cancer treatment
Reglagene RGN6024 Cover Story August 2025 Molecular Cancer Therapeutics
Horse Cremation Memorial Services: Solidified Remains for Beloved Equine Companions
Calls for More Angel Investing
Takes a Licking and Keeps on Ticking
Ventura County firefighters make history with in-the-field blood transfusions
FireRescue1’s “3 Things We’re Watching at FDIC 2025
Delta Ice 1L debut at New Castle Blood Symposium
The next evolution in Prehostial Blood Management
iQure Pharma Receives Approval for iq007 Activity
Tidewater EMS Council Adopts Delta Development Team
Nuvox Therapeutics MHRA Approval Phase IIb Stroke Trial
Interview James Goulka AZ Venture Capital President
Delta Development Team Expands Footprint
iQure Pharma iQ-007 Receives Orphan Drug Status
GT Medical Technologies Raises $37MM